Casirivimab (REGN10933), a human monoclonal antibody targeting the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging variants. When combined with Imdevimab, it significantly lowers viral load and enhances disease outcomes [1].
CAS Number:
[2415933-42-3]
Target:
SARS-CoV
* VAT and and shipping costs not included. Errors and price changes excepted
